CUTISS

Zurich, Switzerland Founded: 2017 • Age: 9 yrs
Personalized skin tissue therapy is developed by CUTISS for surgeries.
Request Access

About CUTISS

CUTISS is a company based in Zurich (Switzerland) founded in 2017 by Daniela Marino and Fabienne Hartmann-Fritsch. It operates as a Product-as-a-Service. CUTISS has raised $94.37 million across 13 funding rounds from investors including Zurcher Kantonalbank, European Union and GISEV. CUTISS offers products and services including denovoSkin™. CUTISS operates in a competitive market with competitors including Humacyte, Tissue Regenix, Acera Surgical, Solsys Medical and Heartseed, among others.

  • Headquarter Zurich, Switzerland
  • Founders Daniela Marino, Fabienne Hartmann-Fritsch
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cutiss Ag
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $94.37 M (USD)

    in 13 rounds

  • Latest Funding Round
    $39.01 M (USD), Series C

    Sep 10, 2025

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CUTISS

CUTISS offers a comprehensive portfolio of products and services, including denovoSkin™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Personalized skin tissue therapy is developed for surgeries.

People of CUTISS
Headcount 10-50
Employee Profiles 12
Employee Profiles
People
Kathi Mujynya
Chief Operating Officer
People
Daniela Marino
Chief Executive Officer
People
Arina Löw
Associate Manager Operations
People
Vincent Ronfard
Chief Innovative Officer

Unlock access to complete

Funding Insights of CUTISS

CUTISS has successfully raised a total of $94.37M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $39.01 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 13
  • Last Round Series C — $39.0M
  • First Round

    (01 Sep 2017)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2025 Amount Series C - CUTISS Valuation

investors

May, 2024 Amount Series C - CUTISS Valuation Cherry Bay Capital Group
Jan, 2022 Amount Grant - CUTISS Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in CUTISS

CUTISS has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, European Union and GISEV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
-
Founded Year Domain Location
Cherry Bay Capital Group is engaged in wealth advisory and investment services.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by CUTISS

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - CUTISS

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cutiss Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of CUTISS

CUTISS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Humacyte, Tissue Regenix, Acera Surgical, Solsys Medical and Heartseed, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Human tissue-based products are developed for vascular disease applications.
domain founded_year HQ Location
Developer of regenerative medical devices by using cell technology
domain founded_year HQ Location
Synthetic electrospun scaffolds are provided for regenerative medical uses.
domain founded_year HQ Location
Human skin allografts and dressings for wound care are supplied.
domain founded_year HQ Location
Developer of myocardial regenerative medicine for treating heart diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about CUTISS

When was CUTISS founded?

CUTISS was founded in 2017.

Where is CUTISS located?

CUTISS is headquartered in Zurich, Switzerland.

Who is the current CEO of CUTISS?

Daniela Marino is the current CEO of CUTISS. They have also founded this company.

Is CUTISS a funded company?

CUTISS is a funded company, having raised a total of $94.37M across 13 funding rounds to date. The company's 1st funding round was a Grant of $339.62K, raised on Sep 01, 2017.

What does CUTISS do?

Skin tissue therapeutics are pioneered by CUTISS, a TechBio company focused on bioengineering. Personalized therapy, denovoSkin, is manufactured for skin surgeries including burns and reconstructive applications. Solutions are produced at a GMP facility in Zurich, Switzerland, using automated, scalable platforms. The technology supports regenerative medicine, space health research, and industrial bioengineered tissues. Expansion into other tissues like gums and cornea is targeted for accessible treatments.

Who are the top competitors of CUTISS?

CUTISS's top competitors include Humacyte, Acera Surgical and Heartseed.

What products or services does CUTISS offer?

CUTISS offers denovoSkin™.

Who are CUTISS's investors?

CUTISS has 10 investors. Key investors include Zurcher Kantonalbank, European Union, GISEV, Rode Kruis Ziekenhuis, and Cherry Bay Capital Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available